Resource Centers
Spotlight
Business
News
Conferences
Partners
CME/CE
Subscribe
- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
5 Facts You Should Know About HIV PrEP
PrEP could work for women too, but there's a gap in HIV rates among this demographic, especially Black women. Outside of PrEP's proven effectiveness, the below facts suggest the need for better promotion and more options.
- Event-driven PrEP for Women: Evidence suggests that event-driven pre-exposure prophylaxis (PrEP) could be as effective for women as it is for men. With non-daily but high adherence, taking four to six pills a week could be as effective at preventing HIV infection as daily dosing, according to a recent study published in JAMA.
- Disparity in HIV Rates: In the U.S., cisgender women accounted for nearly 20% of new HIV cases in 2019, with Black women representing over half of those cases, highlighting a significant disparity in HIV infection rates (CDC).
© nito - stock.adobe.com
- High Effectiveness of PrEP: When taken consistently as prescribed, PrEP can reduce the risk of contracting HIV by up to 99% among individuals at high risk, such as those with HIV-positive partners or engaging in high-risk behaviors, according to clinical trials: iPrEx trial (Grant et al., 2010) and the Partners PrEP trial (Baeten et al., 2012).
- Underrepresentation of Black Women in PrEP Promotion: Outside of its high effectiveness, PrEP uptake among Black women remains low, partly due to historical underrepresentation in PrEP promotion campaigns, which have predominantly featured male couples.
- Expansion of PrEP Options: Efforts to expand PrEP options include developing long-acting injectables and on-demand dosing strategies, aiming to make it easier for folks to stay protected, according to clinical trials: "Long-acting injectable cabotegravir dosing strategies in clinical trials: A review" (ViiV Healthcare, 2021) and "On-demand pre-exposure prophylaxis with oral TDF-FTC in men who have sex with men: A systematic review and meta-analysis" (Cambiano et al., 2019).
Related Videos
Related Content
